Advertisement
Advertisement

TPST

TPST logo

Tempest Therapeutics, Inc. Common Stock

2.90
USD
Sponsored
+0.02
+0.87%
Jan 09, 15:20 UTC -5
Closed
exchange

After-Market

2.85

-0.06
-2.07%

TPST Earnings Reports

Positive Surprise Ratio

TPST beat 21 of 37 last estimates.

57%

Next Report

Date of Next Report
Mar 25, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$3.59
Implied change from Q3 25 (Revenue/ EPS)
--
/
+354.43%
Implied change from Q4 24 (Revenue/ EPS)
--
/
-10.92%

Tempest Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 05, 2025, TPST reported earnings of -0.79 USD per share (EPS) for Q3 25, beating the estimate of -3.33 USD, resulting in a 76.31% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +9.10% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analysts forecast an EPS of -3.59 USD, with revenue projected to reach -- USD, implying an increase of 354.43% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Pharmaceuticals Inc. Common
Report Date
Dec 26, 2025 For Q4 25
Estimate
-$0.49
Actual
-
Surprise
-
FAQ
For Q3 2025, Tempest Therapeutics, Inc. Common Stock reported EPS of -$0.79, beating estimates by 76.31%, and revenue of $0.00, 0% as expectations.
The stock price moved up 9.1%, changed from $9.12 before the earnings release to $9.95 the day after.
The next earning report is scheduled for Mar 25, 2026.
Based on 3 analysts, Tempest Therapeutics, Inc. Common Stock is expected to report EPS of -$3.59 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement